NCT03747224View on ClinicalTrials.gov

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
DyslipidemiasFamilial HypercholesterolemiaHypertriglyceridemia
Interventions
DRUG

ARO-ANG3

single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections

DRUG

sterile normal saline (0.9% NaCl)

calculated volume to match active treatment

Trial Locations (6)

1010

Auckland Clinical Studies Limited, Grafton

2025

Middlemore Hospital, Papatoetoe

2050

Royal Prince Alfred Hospital, Camperdown

5000

Royal Adelaide Hospital, Adelaide

6009

Linear Clinical Research, Nedlands

8011

Lipid & Diabetes Research Group, Christchurch

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY